{"title":"表皮生长因子受体酪氨酸激酶抑制剂治疗后，表皮生长因子受体19-del突变的晚期肺腺癌转变为鳞癌。","authors":"Ruo-Bing Qi, Zheng-Hao Wu","doi":"10.12998/wjcc.v12.i32.6543","DOIUrl":null,"url":null,"abstract":"<p><p>In this editorial we comment on the article by Ji <i>et al</i>. We focus specifically on the EGFR tyrosine kinase inhibitor (EGFR-TKI) treatment and the development of drug resistance to EGFR-TKIs.</p>","PeriodicalId":23912,"journal":{"name":"World Journal of Clinical Cases","volume":"12 32","pages":"6543-6546"},"PeriodicalIF":1.0000,"publicationDate":"2024-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11438645/pdf/","citationCount":"0","resultStr":"{\"title\":\"Advanced lung adenocarcinoma with <i>EGFR</i> 19-del mutation transforms into squamous cell carcinoma after <i>EGFR</i> tyrosine kinase inhibitor treatment.\",\"authors\":\"Ruo-Bing Qi, Zheng-Hao Wu\",\"doi\":\"10.12998/wjcc.v12.i32.6543\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>In this editorial we comment on the article by Ji <i>et al</i>. We focus specifically on the EGFR tyrosine kinase inhibitor (EGFR-TKI) treatment and the development of drug resistance to EGFR-TKIs.</p>\",\"PeriodicalId\":23912,\"journal\":{\"name\":\"World Journal of Clinical Cases\",\"volume\":\"12 32\",\"pages\":\"6543-6546\"},\"PeriodicalIF\":1.0000,\"publicationDate\":\"2024-11-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11438645/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"World Journal of Clinical Cases\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.12998/wjcc.v12.i32.6543\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Clinical Cases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.12998/wjcc.v12.i32.6543","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
摘要
在这篇社论中，我们对 Ji 等人的文章进行了评论。我们特别关注表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）的治疗以及 EGFR-TKIs 耐药性的发展。
Advanced lung adenocarcinoma with EGFR 19-del mutation transforms into squamous cell carcinoma after EGFR tyrosine kinase inhibitor treatment.
In this editorial we comment on the article by Ji et al. We focus specifically on the EGFR tyrosine kinase inhibitor (EGFR-TKI) treatment and the development of drug resistance to EGFR-TKIs.
期刊介绍：
The World Journal of Clinical Cases (WJCC) is a high-quality, peer reviewed, open-access journal. The primary task of WJCC is to rapidly publish high-quality original articles, reviews, editorials, and case reports in the field of clinical cases. In order to promote productive academic communication, the peer review process for the WJCC is transparent; to this end, all published manuscripts are accompanied by the anonymized reviewers’ comments as well as the authors’ responses. The primary aims of the WJCC are to improve diagnostic, therapeutic and preventive modalities and the skills of clinicians and to guide clinical practice in clinical cases.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
